Private Equity's AI Bet: Plenty of Pilots, Limited Proof in the P&L
Private equity adopted AI faster than it has proven the returns. Adoption reached roughly two-thirds of European funds, while around 8% report a material impact on EBITDA or exit value.
Read More
GLM-5.2: A 753B Open Model With 1M Context Reaches Opus-Class Coding
Z.ai's GLM-5.2 is the strongest open-weight, MIT-licensed coding and agentic model, pairing a one-million-token context with frontier-class scores and a US-hosted, zero-retention deployment path for regulated teams.
Read More
Markets June 2026: AI Defies the Hormuz Oil Shock
Les marchés ignorent un choc pétrolier majeur et s'envolent sur l'IA : neutralité active sur les actions, surpondération des métaux et du crédit Investment Grade en euro, prises de profits sur la technologie.
Read More
May 2026 M&A: Algeria Opens, the US Pivots, Switzerland Bridges
May 2026 reframes cross-border M&A around three corridors: Algeria opens, the US pivots, Switzerland bridges. A mid-market playbook for analysts and decision-makers.
Read More
Energy shock, rate repricing, and a European playbook for 2026
April's BNP Paribas Wealth Management note reads like a reminder that markets still misprice energy shocks by treating them as ordinary cycles. When oil and gas prices surge, financial conditions tighten, sentiment cracks, and central banks face an awkward choice: respond forcefully to an inflation print driven by supply constraints, or risk letting expectations drift. The report argues the market has leaned too far into the "three ECB hikes" storyline, while the price action at the end of March already shows the damage a single month of energy stress can do. For executives and investors, the useful frame is practical rather than prophetic. Energy becomes a strategic input with a persistent geopolitical risk premium. Rates become less predictable, even if they ultimately rise less than the futures curve implies. The edge goes to firms that convert volatility into operating discipline: tight working capital, contractual pricing power, energy optionality, and financing structures that survive surprise.
Read More
Neumarz Market Outlook January 2026
2026 M&A trends: why European and Swiss buyers are targeting US assets, plus outlook on healthcare, financial services, and energy consolidation.
Read More
The 2026 Strategic Horizon: Capital Allocation in an Era of Physical Scarcity and Fiscal Dominance
As the 2023-2025 cycle concludes, market consensus suggests a fundamental regime change. The "high nominal growth" era is giving way to a period defined by shrinking cash yields, physical resource constraints, and aggressive industrial policy.
Read More
Neumarz Market Intelligence Brief – November 2025
November 2025 encapsulates that transition. Markets reward foresight, governance and technical mastery. Corporations operating between Switzerland, Western Europe and the United States stand at the frontier of that transformation. Liquidity endures, but leadership belongs to those who know how to use it.
Read More
Europe’s Big AI Bet: How New Guidelines Will Shape the Future of General-Purpose AI Models
Europe’s Bold Step into AI’s Future Setting Clear Boundaries for AI Innovation...
Read More
WCAG vs EAA: Understanding Where WCAG Stops and the EAA Starts
Digital accessibility is increasingly critical for modern organisations. Teams generally understand the importance of meeting Web Content Accessibility Guidelines (WCAG). Yet, to genuinely grasp digital accessibility today, organisations must look beyond WCAG and embrace the broader, more comprehensive requirements of the European Accessibility Act (EAA), guided by EN 301 549 and EN 17161¹.
Read More
Why Non-Financial Benefits Are Becoming the Real Currency of Work
The Conversation That Changed the Tone Emma, 28, walked into her manager’s...
Read More
Ipsen's Strategic Transformation: A Comprehensive Case Study
David Loew took over as CEO of Ipsen during a turbulent period marked by a 70% drop in share price due to the FDA’s hold on palovarotene, a drug for a rare bone disease. Concurrently, their flagship product, Somatuline, faced new generic competition, and the company’s R&D pipeline was heavily skewed towards late-stage assets, posing significant challenges.
Read More